Prabhu M Mukhyaprana, Palaian Subish, Ansari Mukhtar
Department of General Medicine, KMC Manipal, MAHE (deemed to be University), India.
Department of Clinical Sciences, College of Pharmacy and Health Sciences, Ajman University, United Arab Emirates.
Expert Rev Vaccines. 2022 Aug;21(8):1087-1095. doi: 10.1080/14760584.2022.2078311. Epub 2022 May 19.
Fast-track approval has led to serious concerns on the perception of COVID-19 vaccines' safety among the public. Common adverse drug reactions (ADRs) of COVID-19 vaccines are minor localized reactions, while systemic ADRs have been reported rarely. The serious ADRs include anaphylaxis, vaccine-induced immune thrombotic thrombocytopenia syndrome (VITTS), and reactions related to the pharmaceutical excipients present in the vaccine. A comprehensive review on the safety of COVID-19 vaccines would help in early identification and better management of ADRs. This literature review was conducted using PubMed, Google Scholar, COVID-19 Vaccine package inserts, and
This article provides various aspects of COVID-19 vaccine safety and offers strategies to prevent and clinically manage suspected ADRs related to COVID-19 vaccines.
A careful consideration of contraindications and patient education on early identification of serious ADRs are the cornerstones in tackling safety concerns associated with COVID-19 vaccines. Most of the mild ADR cases are manageable with over-the-counter medications, while the serious ones may require physician oversight and hospitalization. It is also mandatory to report all ADRs to the local pharmacovigilance centers, with a higher priority given to the moe significant ones, in order to improve vaccine safety data.
快速审批引发了公众对新冠疫苗安全性认知的严重担忧。新冠疫苗常见的药物不良反应(ADR)为轻微的局部反应,而全身性ADR鲜有报道。严重的ADR包括过敏反应、疫苗诱导的免疫性血栓性血小板减少综合征(VITTS)以及与疫苗中存在的药用辅料相关的反应。对新冠疫苗安全性进行全面综述将有助于早期识别和更好地管理ADR。本综述使用了PubMed、谷歌学术、新冠疫苗说明书以及
本文提供了新冠疫苗安全性的各个方面,并提供了预防和临床管理与新冠疫苗相关的疑似ADR的策略。
仔细考虑禁忌症并对患者进行关于早期识别严重ADR的教育是解决与新冠疫苗相关安全问题的基石。大多数轻度ADR病例可通过非处方药处理,而严重病例可能需要医生监督和住院治疗。还必须向当地药物警戒中心报告所有ADR,对于更严重的ADR给予更高优先级,以改善疫苗安全性数据。